Lopin

Quick links to important sections

Lopin

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lopin

Understanding Lopin

Lopin is a pharmaceutical formulation primarily containing lopinavir, often used in combination with ritonavir. It belongs to a class of medications known as protease inhibitors. These compounds are designed to interfere with the replication process of specific viruses by inhibiting the protease enzyme, which is essential for the cleavage of viral polyproteins into functional units.

Mechanism of Action

The primary component, lopinavir, works by binding to the active site of the viral protease. By preventing this enzyme from functioning, the medication ensures that the virus produces immature, non-infectious particles. This reduction in viral activity helps to manage the progression of the infection within the body.

Ritonavir is typically included in the formulation not for its own antiviral effect at low doses, but as a pharmacokinetic enhancer. It inhibits the metabolic enzymes in the liver that would otherwise break down lopinavir too quickly, thereby maintaining effective concentrations of the primary medication in the bloodstream for longer periods.

Therapeutic Context

Lopin is utilized as part of antiretroviral therapy (ART). While it does not provide a cure for viral infections, it is intended to help control the viral load and support the maintenance of the immune system. It is used in both adult and pediatric populations, depending on the specific clinical requirements and the patient's medical history.

Regulatory References

  1. WHO's List of Essential Medicines
  2. NIH via MedlinePlus

What side effects are possible with Lopin?

Possible Side Effects and Safety Information for Lopin

The safety profile for Lopin, as documented in regulatory files, highlights adverse reactions primarily categorized by the body system affected and their reported frequency.

Adverse Reactions Summary

Adverse reactions associated with Lopin are frequently reported within the Gastrointestinal disorders system-organ class. Reactions such as nausea and vomiting are often categorized as Very common (1/10), particularly during the initial phase of treatment (dose titration).

Frequency Category Key System Organ Class (SOC) Examples of Associated Reactions
Very Common (1/10) Gastrointestinal disorders Nausea, Vomiting
Rare (1/10,000 to < 1/1,000) Respiratory, thoracic, and mediastinal disorders Pulmonary oedema, Interstitial pneumonia

Serious and Clinically Significant Risks

Serious adverse reactions include rare but clinically significant pulmonary events. These may manifest as interstitial pneumonia, pulmonary oedema, and pulmonary infiltrates, which have, in some documented instances, progressed to Adult Respiratory Distress Syndrome (ARDS) and been fatal. Severe hypersensitivity reactions, such as anaphylaxis, are also formally documented safety concerns.

Safety Considerations

Official regulatory documentation notes that patients with a recent history of pulmonary infiltrates or pneumonia are a higher-risk population for developing the severe respiratory complications associated with Lopin exposure.

Specific safety-related restrictions emphasize vigilance regarding the onset of new pulmonary signs, such as fever, cough, or dyspnoea, as these symptoms may signal the potential onset of ARDS. This monitoring requirement is defined within formal risk minimisation measures.

This summary reflects the structured safety information derived from governmental health authority documents (e.g., EMA/FDA), categorizing risks based on established frequency frameworks and MedDRA System Organ Classes for consistent safety surveillance.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Lopin (Amlodipine) is characterized by documented physiological effects that reflect an exaggerated extension of its therapeutic action, primarily excessive peripheral vasodilation.

This leads to clinical manifestations of marked and potentially prolonged systemic hypotension (low blood pressure), often accompanied by reflex tachycardia (rapid heartbeat). Severe overdose carries the risk of progression to shock and potentially a fatal outcome.

Urgent medical attention is required for any suspected massive overdose. Regulatory authorities mandate that patients seek immediate medical attention and call emergency services (911) immediately if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Contacting the poison control helpline is also a documented action.

Management is symptomatic and supportive, as no specific antidote is known. Due to the drug's long elimination half-life, active cardiovascular and respiratory monitoring is required, often necessitating an overnight hospital stay even in less severe cases. Supportive measures, which may include judicious fluid administration and vasopressors for refractory hypotension, are focused on stabilizing cardiovascular function.

Therapeutic Uses of Lopin

What Lopin treats: Main Uses and Benefits

Lopin is considered relevant for use in conditions characterized by chronic high blood pressure, which presents with symptoms related to systemic imbalance that create noticeable physiological strain. It is generally applied in contexts involving heightened systemic burden to support pressure regulation. The therapeutic areas for which it is commonly used involve conditions such as hypertension, chronic stable angina, and vasospastic angina.


This assists with contributing to sustaining pressure regulation throughout the day, thereby helping to ease the functional strain on the heart and blood vessels. The medication is commonly used for easing symptoms related to physical discomfort arising from recurrent episodes of ischemic chest discomfort. It is applied across therapeutic domains where additional symptomatic support is needed to address symptoms that interfere with daily comfort. This treatment may assist with maintaining functional stability by helping to reduce the frequency and intensity of these distressing manifestations. Lopin is also applied in broader long-term therapeutic strategies for conditions characterized by increased physiological stress, such as documented Coronary Artery Disease (CAD).

“It is commonly used across conditions presenting with recurrent or episodic manifestations where supportive symptom management is appropriate.”

Quick Fact: Relevant for Managing Recurrent Chest Discomfort and Systemic Pressure Overload.

Eligibility and Restrictions for Use

The eligibility for using Lopin (Amlodipine) is determined by official regulatory documents, which define approved populations and strict contraindications.


Contraindicated Populations (Must Not Use)

Classification Population/Condition
Absolute Contraindication Known hypersensitivity to Amlodipine or other dihydropyridine derivatives.
Absolute Contraindication Patients experiencing severe hypotension, shock (including cardiogenic shock), or high-grade aortic stenosis.
Absolute Contraindication Patients with haemodynamically unstable heart failure following a heart attack.

Age and Health Restrictions

Eligibility Status Population Group
Approved Use Adults (18+). Children/Adolescents (6–17 years) only for hypertension treatment.
Use Not Established Children under 6 years of age for hypertension.
Conditional Use Patients with hepatic impairment (liver dysfunction) require caution, typically starting at a lower dose due to reduced clearance.
Conditional Use Older adults should have dose increases implemented with care.
Restricted Status Pregnancy: Use is generally not recommended unless the potential benefit justifies the risk. Lactation: Discontinuation of nursing is recommended as Amlodipine is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lopin (Amlodipine) is subject to officially documented interaction patterns primarily concerning its metabolic pathway and pharmacodynamic effects, as noted in government regulatory labeling.

Documented Interaction Constraints

Co-administration with intravenous Dantrolene is a contraindicated combination, based on the formal regulatory finding of a specific risk for hyperkalemia. The use of strong and moderate CYP3A4 inhibitors (e.g., Clarithromycin) is officially associated with a significant increase in Amlodipine systemic exposure. Conversely, strong CYP3A4 inducers (e.g., Rifampicin, St. John’s Wort) may lead to variable changes in plasma levels and potential reduced efficacy.

Restrictions on Co-administered Products

Amlodipine can alter the exposure of other medicines; for example, the regulatory restriction for Simvastatin mandates limiting its dose to 20 mg daily due to documented increases in Simvastatin plasma concentration. The simultaneous use of other antihypertensive agents results in an officially documented additive blood pressure lowering effect. Monitoring is required for co-administered immunosuppressants, such as Tacrolimus and Cyclosporine, as Amlodipine may increase their blood levels.

Food and Population Notes

The consumption of grapefruit or grapefruit juice is not recommended as it may increase the drug's bioavailability. Interaction effects may be more pronounced in elderly patients and those with severe hepatic impairment due to altered pharmacokinetics.

Mechanism of Action

How Lopin Works

Lopin's mechanism of action is defined by its selective influence on the electrical and contractile properties of the cardiovascular system, achieved through two main mechanistic domains.


Targeting L-Type Calcium Channels for Vascular Inhibition

The drug acts at the molecular level by directly blocking the Voltage-dependent L-type Calcium Channels (Cav1.2) found in the walls of the arteries. This molecular intervention functions as a slow-channel blockade, effectively preventing the necessary influx of extracellular calcium ions (Ca^2+) into vascular smooth muscle cells. This action initiates the physiological cascade by inhibiting the primary trigger for muscle contraction.


Cascade from Smooth Muscle Relaxation to Afterload Reduction

The inhibition of calcium influx disrupts the Excitation-Contraction Coupling Pathway, leading to a state of relaxation (vasodilation) of arterial smooth muscle. Because Lopin is highly vasoselective, this effect is maximized in the peripheral and coronary arteries, leading to a decrease in the overall resistance the heart must pump against. This reduction in the heart's afterload is a principal physiological consequence resulting from the drug's mechanism.

Dosage and Administration Information

Lopin is administered exclusively via the oral route, typically supplied as 2.5 mg, 5 mg, and 10 mg tablets. The medication is prescribed for long-term chronic therapy.

Standardized Administration Principles

The standard protocol for using Lopin is based on a once-daily dosing schedule, which is consistent with its long duration of action. The medication should be taken at approximately the same time each day to maintain consistent drug levels. Lopin can be consumed with or without food, as the drug's absorption is not significantly affected by meal consumption.

Official Dosing Regimens

  • Adult Initial Dose: The starting oral dose is commonly 5 mg once daily.
  • Maintenance Dose Range: Doses typically range from 5 mg to 10 mg once daily.
  • Maximum Dose: The highest approved daily dose for adults is 10 mg.

Procedural Guidelines

Any dose increase must be executed gradually, with a titration interval of 7 to 14 days between adjustments to allow for a full assessment of the clinical response. A lower initial dose of 2.5 mg once daily is used for older or frail patients, as well as those with confirmed hepatic impairment. For children 6 to 17 years being treated for hypertension, the maximum approved dose is 5 mg once daily.

Missed Dose Protocol: If an administration is forgotten, it should be taken as soon as the lapse is noted on that day. However, two doses must not be taken simultaneously to compensate for the skipped dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lopin (Amlodipine)


Evidence for use in Hypertension (High Blood Pressure)

The research on Lopin was studied for its use in high blood pressure and involved a significant number of Randomized Controlled Trials (RCTs) and large-scale, long-term cardiovascular outcome trials. These studies were conducted to explore outcomes in various adult populations with essential hypertension. Researchers primarily studied two key measures: how the medication affected the actual Systolic and Diastolic Blood Pressure (SBP/DBP) readings, and whether patterns related to the rates of major cardiovascular events, such as heart attack or stroke, were observed over time.

Regulatory assessments of these trials describe patterns related to the measured change in both SBP and DBP in the studied populations. Long-term outcome trials, in particular, examined the occurrence rates of major cardiovascular events, providing data that contributes to the broader evidence landscape regarding blood pressure management. The findings overall describe patterns observed in the studies.


Evidence for use in Chronic Stable and Vasospastic Angina

Lopin was evaluated in research exploring its use in conditions characterized by chest pain, including both chronic stable angina and vasospastic angina. The research examined short-term episodic symptom patterns using controlled trial designs. The main outcomes related to physical discomfort that were measured included the frequency of angina episodes, as recorded in patient diaries, and the amount of rescue medication used. Researchers also monitored functional measures, such as change in exercise tolerance time.

Across these symptomatic studies, regulators noted that the trials reported how symptoms evolved in the observed populations, including documented measurements of episode frequency and rescue medication usage. This research provides insight into short-term changes in these outcomes reflecting daily functioning or activity level. Dedicated trials for vasospastic angina, while typically smaller due to the condition's lower prevalence, described patterns related to the control of these episodes.


Evidence in Specific Patient Populations

Lopin was studied for its application in several distinct groups beyond the general adult population. Research explored outcomes in older adults with hypertension, and specific trials examined blood pressure readings in studies monitoring physiological strain or stress in children aged six years and older. The findings in these older adult populations and in children are contributing to the broader evidence landscape used by regulators to assess its use in these age ranges.


Research Gaps and What Remains Uncertain

While Lopin has been the subject of extensive research, several areas remain uncertain or require further data collection. Data for certain groups remain insufficient, specifically for children under the age of six with high blood pressure. Furthermore, the generalizability of some large outcome trials is limited because they intentionally excluded patients with pre-existing conditions, such as significant heart failure. This means the specific event-reduction findings apply only to the populations studied and do not fully address the outcomes in those higher-risk patient groups.

Frequently Asked Questions (FAQ)

Common questions about Lopin (FAQ)

Q: How long does it typically take to feel the effects of Lopin?

Official product information, based on pharmacokinetic studies, describes that the amount of the drug in the bloodstream typically reaches its highest level, or peak concentration, between 6 and 12 hours after taking Lopin by mouth. This measurement helps professionals understand the drug's absorption rate.

Q: Does Lopin interact with common over-the-counter pain relievers?

Regulatory information indicates that interactions between Lopin and certain common pain relievers, specifically Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like ibuprofen, may occur. Official guidance notes that NSAIDs can potentially cause blood pressure to increase in some instances, which may affect Lopin's purpose.

Q: Is it true that Lopin might affect sleep patterns?

Some patients using Lopin have reported experiencing sleep disturbances, such as insomnia (difficulty sleeping). Official safety documents confirm these reports, although this effect is generally not listed as a very common side effect.

Q: Is Lopin available as a generic medicine?

Yes, Lopin's active ingredient, Amlodipine, is available as a generic tablet from multiple manufacturers. Regulatory bodies have approved these generic forms as equivalent to the original product.

Q: What is the risk of dependence or addiction with Lopin?

According to official regulatory status documents, Lopin (Amlodipine) is not classified as a controlled substance. This means the medication does not fall under the controlled substance schedules.

Q: Are there different strengths or forms of Lopin available?

Official product information states that Lopin is typically supplied as oral tablets in three main strengths: 2.5 mg, 5 mg, and 10 mg. In addition to the tablets, other formulations, such as solutions, may be available in clinical settings for specific patient needs.

Q: Can Lopin be used if I have kidney issues?

Regulatory documents indicate that the way Lopin is processed by the body is not significantly altered by kidney impairment. Therefore, the official guidance states that a change in dosage is typically not necessary for patients with kidney issues.

Q: What should I know about Lopin and driving?

Official product information notes that Lopin may cause certain side effects, including dizziness, drowsiness, or fatigue. If these effects occur, official warnings advise that activities requiring mental alertness, such as driving or operating complex machinery, may be impaired.

Q: Can Lopin be taken with antacids?

There is evidence that certain antacids, such as those containing calcium carbonate, may decrease the effects of Lopin. Information regarding the co-administration of Lopin and antacids should be discussed with a healthcare provider.

Q: Is Lopin a controlled substance?

Lopin (Amlodipine) is a prescription-only medicine but is not classified as a controlled substance.

Q: What if I'm taking vitamins; do they interact with Lopin?

Regulatory sources indicate that taking Lopin alongside multivitamins that contain certain minerals may potentially decrease Lopin's intended effects. Official guidance recommends discussing co-administration with a healthcare provider.

Q: Is it normal to feel a bit tired when first taking Lopin?

Official product information states that feeling tired or experiencing fatigue is listed as a common side effect of Lopin. This effect is often reported to occur especially during the initial phase of treatment.

Q: Can Lopin be used by women who are planning a pregnancy?

Official regulatory documents generally advise that Lopin is not recommended during an active pregnancy unless deemed clearly necessary. There is currently no well-controlled data from studies that specifically addresses use during the pre-conception or planning phase.

Q: How is Lopin removed from the body?

According to the pharmacokinetics (how the drug moves through the body) sections of the regulatory label, Lopin is primarily broken down, or metabolized, by the liver into inactive components. The majority of these broken-down components are then eliminated from the body by the kidneys through the urine.

Q: Are there any widely known warnings about stopping Lopin suddenly?

While not a dedicated warning on Lopin's specific label, official regulatory guidance often advises against the sudden discontinuation of any medication used to treat high blood pressure. Stopping abruptly may potentially cause a sharp rise in blood pressure, sometimes referred to as a rebound effect.

Q: Is Lopin known to cause skin reactions or rashes?

Official safety documents indicate that skin rashes or pruritus (itching) are known adverse events associated with Lopin. Furthermore, in rare instances, severe skin reactions and hypersensitivity events have been formally documented.

Q: Can Lopin be crushed or split?

Lopin is typically supplied as film-coated oral tablets. In clinical practice, guidance has been established indicating that Lopin tablets may be dispersed or dissolved in water for immediate administration, particularly for patients who have difficulty swallowing whole tablets.

Q: Does Lopin cause any changes in mood or behavior?

Reports indicate that changes in mood, such as depression or nervousness, have been observed, generally in post-marketing experience. Official product information lists these under effects related to the nervous system and psychiatric disorders, although they are not common occurrences.

Q: What does 'contraindicated' mean for Lopin users?

The term contraindicated means that the medication should not be used because there is an officially determined risk. A contraindication exists when the potential harm of using Lopin outweighs any possible benefit due to a specific pre-existing condition, such as a severe allergy, or concurrent treatment.

Q: Can I take Lopin if I already take a daily aspirin?

Regulatory sources note that interactions may occur between Lopin and low-dose aspirin, which could potentially lead to changes in blood pressure. Information regarding the co-administration of Lopin and aspirin should be discussed with a healthcare provider.

Q: Can Lopin affect the results of blood work?

Official product information notes that changes in certain laboratory parameters have been reported. For instance, elevations in liver enzymes have been observed in some patients, though this is generally not considered a common occurrence.

Q: How is the safety of Lopin monitored after it's approved?

The safety of Lopin is monitored after it reaches the market through pharmacovigilance systems. These regulatory systems require drug manufacturers to submit periodic safety reports on all observed adverse events to ensure ongoing surveillance by health authorities.

How should Lopin be stored and disposed of?

Storage Conditions and Handling

Lopin (amlodipine) tablets must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), with temporary excursions permitted up to 30 C (86 F). The medication must be protected from light and excess moisture, requiring it to be kept in the container it came in and that container must be tightly closed. Storage in damp areas like bathrooms should be avoided.

Child Safety and Disposal

All Lopin medication must be stored strictly out of the reach and sight of children; safety caps should always be secured. For disposal of unused or expired tablets, official guidelines recommend using a drug take-back program. If a take-back program is unavailable, the medication must be mixed with an unappealing substance, sealed in a container, and disposed of in household trash; it should not be flushed down a toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lopin found in:

A-Z Index: